Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Acrux Limited (ACR.AX)
AUD0.01
+0.00 (+0.00%)
AU ASX Healthcare Biotechnology
Address
103-113, Stanley Street 3003
West Melbourne, VIC, AU
West Melbourne, VIC, AU
CEO
John Warmbrunn
Website
acrux.com.au
IPO
2004-09-29
ISIN AU000000ACR3
Also trades on
Australian Securities Exchange · ACR.AX (AUD)
Other OTC · ARUXF (USD)
Description
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.01
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.99
Float Shares
379.22M
Free Float %
92.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.69% | +33.33% | +0.00% | -7.69% | -20.00% | -20.00% | -47.83% | -73.33% | -91.11% | -98.30% | -98.80% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.01
Ratings Trend (MoM)
| Rating | 2025-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-45.59
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-76.6% Q4'25: -60.5% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+15.5% Q4'25: +103.6% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-478.3% Q4'25: -239.2% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-473.5% Q4'25: -74.2% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-148.5% Q4'25: -79.6% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+21.6% Q4'25: +42.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.70× Q4'25: -0.85× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2007 actual |
Jun 2008 actual |
Jun 2009 actual |
Jun 2010 actual |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.90M
est: 5.58M (-48.1%)
|
4.50M
est: 4.08M (+10.3%)
|
650.0K
est: 553.2K (+17.5%)
|
54.90M
est: 29.21M (+87.9%)
|
89.60M
est: 115.73M (-22.6%)
|
8.80M
est: 8.58M (+2.5%)
|
15.55M
est: 13.75M (+13.1%)
|
53.86M
est: 55.52M (-3.0%)
|
25.37M
est: 24.00M (+5.7%)
|
28.56M
est: 28.63M (-0.3%)
|
23.93M
est: 24.00M (-0.3%)
|
3.43M
est: 28.63M (-88.0%)
|
631.0K
est: 180.43M (-99.7%)
|
1.25M
est: 3.00M (-58.2%)
|
1.34M
est: 3.00M (-55.4%)
|
1.72M
est: 8.00M (-78.5%)
|
5.09M
est: 6.50M (-21.7%)
|
1.19M
est: 6.90M (-82.8%)
|
11.90M
11.90M – 11.90M
+72.5% YoY
|
14.20M
14.20M – 14.20M
+19.3% YoY
|
| EBITDA |
-9.33M
est: -14.44M (+35.4%)
|
-6.42M
est: -5.92M (-8.3%)
|
-9.98M
est: -706.9K (-1,311.0%)
|
49.89M
est: -375.47M (+113.3%)
|
83.56M
est: -100.26M (+183.3%)
|
3.62M
est: 5.99M (-39.6%)
|
10.89M
est: 8.25M (+31.9%)
|
45.23M
est: 41.10M (+10.0%)
|
16.95M
est: 20.60M (-17.7%)
|
20.80M
est: 17.81M (+16.7%)
|
12.13M
est: 12.27M (-1.1%)
|
-9.33M
est: -80.9K (-11,426.9%)
|
-12.67M
est: -6.87M (-84.4%)
|
-11.37M
est: -3.56M (-219.0%)
|
-15.59M
est: -2.60M (-499.7%)
|
-12.29M
est: -6.93M (-77.3%)
|
-8.07M
est: -5.63M (-43.2%)
|
-5.17M
est: -5.98M (+13.6%)
|
-10.31M
-10.31M – -10.31M
-72.5% YoY
|
-12.30M
-12.30M – -12.30M
-19.3% YoY
|
| EBIT |
-9.85M
est: -14.64M (+32.8%)
|
-6.90M
est: -5.56M (-24.0%)
|
-10.57M
est: -590.3K (-1,691.4%)
|
49.41M
est: -439.36M (+111.2%)
|
83.31M
est: -101.89M (+181.8%)
|
3.27M
est: 6.24M (-47.7%)
|
9.46M
est: 7.50M (+26.2%)
|
45.10M
est: 40.01M (+12.7%)
|
16.81M
est: 21.80M (-22.9%)
|
18.86M
est: 17.47M (+8.0%)
|
11.04M
est: 13.36M (-17.3%)
|
-10.98M
est: 53.3K (-20,697.2%)
|
-12.99M
est: -6.71M (-93.6%)
|
-12.08M
est: -3.56M (-238.9%)
|
-16.25M
est: -2.64M (-515.3%)
|
-12.97M
est: -7.04M (-84.1%)
|
-8.58M
est: -5.72M (-49.8%)
|
-5.63M
est: -6.08M (+7.3%)
|
-10.48M
-10.48M – -10.48M
-72.5% YoY
|
-12.50M
-12.50M – -12.50M
-19.3% YoY
|
| Net Income |
-7.86M
est: -14.54M (+45.9%)
|
-5.03M
est: -5.74M (+12.4%)
|
-7.72M
est: -682.5K (-1,030.5%)
|
46.55M
est: -407.68M (+111.4%)
|
57.15M
est: 184.42M (-69.0%)
|
7.39M
est: 4.24M (+74.5%)
|
6.93M
est: 11.84M (-41.5%)
|
27.97M
est: 27.98M (0.0%)
|
11.13M
est: 13.52M (-17.7%)
|
12.98M
est: 11.68M (+11.1%)
|
-243.0K
est: 9.19M (-102.6%)
|
-14.18M
est: -35.7K (-39,637.7%)
|
-8.33M
est: -5.97M (-39.4%)
|
-9.47M
est: -3.56M (-166.1%)
|
-12.63M
est: -17.61M (+28.3%)
|
-9.83M
est: -10.56M (+6.9%)
|
-5.80M
est: -4.23M (-37.2%)
|
-5.95M
est: -3.87M (-53.5%)
|
2.11M
2.11M – 2.11M
+154.5% YoY
|
4.23M
4.23M – 4.23M
+100.0% YoY
|
| SGA |
4.87M
est: 17.59M (-72.3%)
|
5.15M
est: 12.84M (-59.9%)
|
4.67M
est: 1.74M (+168.0%)
|
2.89M
est: 92.02M (-96.9%)
|
3.25M
est: 14.90M (-78.2%)
|
3.32M
est: 327.6K (+914.7%)
|
2.95M
est: 5.99M (-50.8%)
|
4.21M
est: 14.13M (-70.2%)
|
4.97M
est: 2.08M (+139.2%)
|
5.19M
est: 5.25M (-1.2%)
|
7.26M
est: 3.68M (+97.5%)
|
8.48M
est: 1.07M (+695.2%)
|
6.96M
est: 3.57M (+94.9%)
|
7.61M
est: 2.98M (+155.8%)
|
8.00M
est: 9.45M (-15.4%)
|
7.65M
est: 25.20M (-69.6%)
|
1.49M
est: 20.48M (-92.7%)
|
5.77M
est: 21.74M (-73.5%)
|
37.49M
37.49M – 37.49M
+72.5% YoY
|
44.73M
44.73M – 44.73M
+19.3% YoY
|
| EPS |
-0.06
est: -0.04 (-30.8%)
|
-0.03
est: -0.04 (+12.3%)
|
-0.05
est: -0.06 (+13.7%)
|
0.29
est: 0.28 (+1.8%)
|
0.35
est: 0.42 (-16.2%)
|
0.04
est: 0.04 (+9.9%)
|
0.04
est: 0.04 (+4.0%)
|
0.17
est: 0.20 (-15.1%)
|
0.07
est: 0.07 (-9.1%)
|
0.08
est: 0.09 (-10.3%)
|
0.00
est: 0.07 (-102.0%)
|
-0.09
est: 0.09 (-198.0%)
|
-0.05
est: 0.03 (-272.4%)
|
-0.06
est: -0.06 (+5.8%)
|
-0.06
est: -0.05 (-15.0%)
|
-0.03
est: -0.03 (-15.3%)
|
-0.02
est: -0.01 (-66.7%)
|
-0.02
est: -0.01 (-53.6%)
|
0.01
0.01 – 0.01
+154.5% YoY
|
0.01
0.01 – 0.01
+100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-13.75M
OE per share TTM
-0.04
Owner's Yield
-279.01%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
81.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-1.3K
Shares Outstanding
410.61M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| John Warmbrunn | MD, Chief Executive Officer & Director | 366.7K | male |
| Joanna Johnson ICAA | Chief Financial Officer & Company Secretary | 301.3K | female |
| Felicia Colagrande | Product Development & Technical Affairs Director | 295.3K | female |
| Mark Hyman | Project & Technical Development Director | 288.8K | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACR.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
